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1. Introduction 
Simple point mutations can confer profound phenotypes on pathogens and parasites of 
major public health importance, such as malaria. In particular, single nucleotide 
polymporphisms (SNPs) are known to easily arise, where one base changes occur in the 
parasite genomic sequence. These SNPs may confer resistance to malaria therapeutic or 
preventive drugs, or even render other as yet uncharacterized phenotypes of public health 
concern, such as virulence. Modern advances in parasite molecular biology and genomics 
allow the typing of parasites with a range of levels of detail. Particular SNPs or 
combinations of these are identified which are associated with resistance, followed by 
confirmation through genetic cross experiments. Using simple polymerase chain reaction 
(PCR) techniques, the point mutations are now increasingly applied as molecular markers 
for tracking and containment of resistant malaria. These marker point mutations are 
particularly instrumental surveillance tools as they enable efficient detection of drug-
resistant parasites or pathogens before escalation to a public health toll. 
1.1 Drug resistance and malaria control 
Malaria persists as a major global public health problem, affecting more than 100 countries 
in Africa, Asia, the South Pacific region, Latin America and the Indian sub-continent, as well 
as a vast assemblage of non-immune travellers continually visiting such areas. 
Notwithstanding substantial technological advances, the old scourge currently claims a 
global toll of 225 million cases and 781,000 deaths every year, mostly children in Africa [1,2]. 
This has been a relative improvement from 500 million cases and at least 2.3 million annual 
deaths that were occurring as recently as early-mid 2000s [3,4], with an escalating trend in 
overall burden of the disease. Thanks to the Roll Back Malaria programme, the President’s 
Malaria Initiative and other public-private sector initiatives, and notably the Bill and 
Melinda Gates Foundation, endemic countries have scaled up vector control and 
artemisinin-based combination therapy (ACT) interventions against malaria[5,6], resulting 
in widespread reduction of burden[7,8]. A number of countries have presently been 
earmarked for possible local or regional malaria elimination[9,10], including those in 
southern Africa, which are located towards the natural fringes of transmission. However, 
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the resilient scourge prevails in significant segments of resident communities as 
asymptomatic[11] and often low-grade, sub-microscopic[12] infections. 
Recent epidemiological studies have shown a striking link between availability of effective 
treatment drugs and historical successes in major reduction of the burden of malaria 
throughout the world[13,14]. Correspondingly, the emergence of antimalarial drug 
resistance, especially in Plasmodium falciparum, has proved a major obstacle for malaria 
control and elimination efforts since the eradication campaigns of the 1950s[15,16,17,18,19]. 
Drug resistance in P. ovale and P. malariae has not been documented, while in P. vivax the 
phenomenon, has been recently increasing[20,21,22].  
The potential of the malaria parasite to generate genetic diversity through its complex 
genome and a proliferative life cycle involving sexual and asexual stages, means that drug 
resistance will remain a problem to contend with, escalating in the wake of wider 
introduction of each antimalarial. P. falciparum has repeatedly demonstrated this adaptation 
against virtually all antimalarial drugs[23,24,25], including the new regimens with or 
without artemisinin[26,27,28,29]. To minimize suffering and mortality due to use of drug 
regimens which are no longer effective, the epidemiology of drug resistance in malaria 
endemic regions needs continual monitoring[6].  
1.2 Definition of drug resistance 
Because of the immense amount of work that has gone into the subject, a number of related 
terms have evolved around “drug resistance”, with distinguishable applications, depending 
on the objectives of the characterization and methods used. These are summarized as 
follows, for clarity.   
1.2.1 Classical definition of drug resistance 
Antimalarial drug resistance has been defined as “the ability of a parasite strain to survive 
and (or) multiply despite administration and absorption of the usually recommended, or 
slightly higher doses of a drug, within limits of tolerance of the host”[30,31]. This original 
definition generally holds for most drugs, but in the light of the pharmacokinetic 
characteristics of some antimalarials, a qualification was subsequently added, that “the form 
of the active drug against the parasite must gain access to the parasite, or the infected 
erythrocyte, for the duration of time necessary for its normal action”[32]. The qualification 
was added to cater for drug bioavailability and narrow down the reason of drug failure to 
parasite resistance. This definition of drug resistance therefore, in the strict sense, attempts 
to centre on the response of a parasite to an antimalarial, excluding host factors. Resistance 
has been assayed by in vitro methods, primarily based on the system developed by 
Rieckman et al[33].  In vivo methods[19,31] have also been used, but discrepancies with in 
vitro findings have been common because host factors, especially immunity, cannot be 
entirely precluded in vivo. 
1.2.2 Therapeutic failure concept 
For public health purposes, the importance and relevance of in vivo resistance has been 
increasingly recognized in drug policy decisions[34,35] since it is net parasite response to 
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antimalarial medication in the human host that is paramount. However, in vivo resistance 
can, and indeed has, still occurred without much clinical relevance in the human population 
of interest, which may harbour resistant parasitaemias asymptomatically, especially in 
endemic areas[36,37]. Over time in vivo approaches have therefore been progressively 
modified to assess the parasitological and clinical response to antimalarial drugs[38,39,40]. 
These approaches measure the therapeutic efficacy of antimalarials and the corresponding 
parasitological and clinical resistance, which is termed therapeutic failure. Drug resistance 
per se may or may not lead to therapeutic failure, depending on malaria endemicity and 
concomitant level of immunity in the resident populations. 
1.2.3 Treatment failure 
Under routine operational conditions in primary health care, resistance parasitologically 
and (or) clinically is frequently encountered. It is usually not feasible in these situations to 
completely supervise drug administration and confirm bioabsorption. The apparent 
resistance is termed treatment failure, and may be caused by true drug resistance, 
malabsorption or incomplete dose compliance by outpatients. 
1.2.4 Summary 
Albeit often confused and interchangeably used, the foregoing terms have distinct 
applications. In this chapter drug resistance refers to the original sense, based on parasite 
response as ascertained in vivo or in vitro. Where reference to the other conditions is made 
the appropriate terms shall be used. 
2. Armamentarium of current antimalarials and mode of action 
Despite a seemingly extensive list of potent compounds, the net armamentarium of 
effective, safe and usable antimalarials is limited, relative to the epidemiological magnitude 
and evolutionary potential of malaria parasites. Owing to the advent of drug resistance, 
there is a need to develop more antimalarials. The antimalarial drugs in current use can in 
effect be grouped into blood schizontocides and antimetabolites of the folate pathway. 
2.1 Blood schizontocides 
Blood schizontocides act directly on intraerythrocytic stages responsible for symptoms and 
tend to be fast acting compounds usually preferred for treatment of acute disease. They 
include: aryl amino alcohols; 4-aminopyridine analogues; and the more recently widely 
introduced artemisinin and derivatives. Compounds in the first two groups are often 
referred to as quinoline-containing drugs (QCD’s).  
The aryl amino alcohols include the old cinchona alkaloid drug, quinine; the 
quinolinemethanol, mefloquine; and the phenanthrenemethanol drug, halofantrine. Quinine 
has been used for treatment and, in some cases prophylaxis, since the 17th century, as crude 
cinchona (Peruvian) bark, and from the 19th century as the pure drug. In contrast, 
halofantrine is a relatively new compound, which was first registered in France and 
francophone African countries in 1988. The 4-aminopyridine analogues include 
amopyraquine, mepacrine and the 4-aminoquinolines: chloroquine and amodiaquine. The 4-
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aminoquinolines were introduced among the first generation of synthetic antimalarials in 
the late 1940’s, following the search for safer compounds, for use both as treatment and 
prophylaxis. Artemisinin and derivatives include the parent compound artemisinin, a 
sesquiterpene lactone which constitutes the active principle of the Chinese herb quingaosu, 
and its derivatives. The Chinese herb was used for hundreds of years to cure malarial fevers, 
but only recently purified and introduced on a wider scale for treatment of multidrug-
resistant malaria. Water and oil-soluble derivatives of artemisinin were subsequently 
developed which include the salt, sodium (or potassium) artesunate; the methyl ether 
derivative, artemether; and the ethyl ether derivative, arteether. 
Blood schizontocides are believed to target the haemoglobin digestion and excretion process 
in the parasite food vacuole. Chloroquine, one of the 4-aminoquinolines most extensively 
studied, is thought to act by inhibiting polymerization of the parasite’s haemoglobin 
digestion by-product, haem (ferriprotoporphyrin IX), which is toxic to the parasite if 
allowed to accumulate[41]. The non-toxic polymer that the parasite generates in the absence 
of inhibiting drug is haemozoin, or malaria pigment. Artemisinin and its derivatives have a 
unique endoperoxide bridge that is thought to undergo reactive cleavage by 
ferriprotoporphyrin IX. This generates free carbon-centred radicals that alkylate 
biomolecules and kill the parasite cells.  
2.2 Antimetabolites of the folate pathway 
Antimetabolites of the folate pathway (often referred to as antifolates) tend to attack all 
growing stages of the malaria parasites, including the early growing stages in the liver 
(causal prophylactic effect) and developing infective stages in the mosquito (antisporogonic 
effect). Like 4-aminoquinolines, the antimetabolites were also introduced in the late 1940’s. 
They include the dihydrofolate reductase (DHFR) inhibitors (pyrimethamine, trimethoprim, 
cycloguanil and chlorcycloguanil) and dihydropteroate synthetase (DHPS) inhibitors or 
sulfa drugs (sulfadoxine, sulfalene, dapsone, sulfamethoxazole). Antifolates are usually 
used as combinations, e.g. sulfadoxine/pyrimethamine, sulfalene/pyrimethamine, or 
dapsone/pyrimethamine (prophylaxis). 
The mode of action of antifolate drugs is among the most well understood. Malaria parasites 
synthesize folates during biosynthesis of pyrimidines which they cannot scavenge from the 
host. Antifolate drugs block two sequential steps within the folate synthesis pathway, 
eventually leading to (i) decreased pyrimidine synthesis and arrest of DNA replication; (ii) 
decreased methionine and serine production; and (iii) ultimate cell cycle arrest and death of 
the parasites. Dihydrofolate reductase inhibitors act by competing with substrate for the 
enzyme dihydrofolate reductase, while sulfa drugs are paraminobenzoic acid (PABA) 
analogues which competitively inhibit dihydropteroate synthetase in the preceding reaction. 
3. Mechanisms of drug resistance  
3.1 Quinoline-containing drugs 
3.1.1 Group I blood schizontocides 
Group I blood schizontocides are the dibasic QCD’s, mainly the 4-aminoquinolines.  
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The mechanism of resistance to these drugs is due not to altered drug target, but to reduced 
drug accumulation in the parasite food vacuole[42]. Resistant parasites survive by 
accumulation of less drug than their sensitive counterparts. How the low drug levels are 
accumulated in resistant parasites is still not fully understood. A drug efflux mechanism has 
been proposed [43,44], and so has reduced drug uptake[45,46].  
Enhanced Drug Efflux 
Chloroquine-resistant isolates are known to expel intracellular chloroquine 40-50 times as 
rapidly as chloroquine-sensitive strains[44]. This process is energy-dependent and 
susceptible to ATP blockage[43]. Compelling evidence for a drug efflux mechanism has been 
the demonstration of reversal of chloroquine resistance by calcium channel blockers such as 
verapamil as well as some tricyclic compounds such as desipramine, in vitro and in 
vivo[47,48,49]. Reversal of chloroquine resistance by verapamil is independent of the weak 
base effect and is specific to resistant strains[50]. Although there were conflicting findings 
among earlier in vivo studies[51], subsequent work has abundantly illustrated chloroquine 
resistance reversal in malaria patients, with the antihistaminic agent 
chlopheniramine[52,53], and with promethazine[54]. The observations on reversal of 
chloroquine resistance by calcium channel blockers have led to the theory that a similar 
system to the multidrug resistance (mdr) phenomenon in mammalian cancer cells[55] is 
responsible. The mdr phenomenon in mammalian cancer cells is mediated by an ATP-
dependent transporter, P-glycoprotein, which resides on the surface of the cell and has 
affinity for a wide range of compounds, including anti-cancer drugs which it actively expels. 
The mammalian mdr phenotype is reversed by a broad range of compounds that compete 
for affinity for the P-glycoprotein, including calcium channel blockers like verapamil, 
calmodulin antagonists and other compounds. P-glycoprotein homologues were 
subsequently isolated in Plasmodium falciparum, pfPgh1 and pfPgh2[56] encoded by the 
genes Pfmdr1 and Pfmdr2. 
These genes have shown partial association with chloroquine resistance controversy, with 
some workers reporting no association between Pfmdr1 and chloroquine resistance[57], 
although the chloroquine efflux trait genetically segregated as a single locus[58]. Others 
have reported amino acid changes in Pfmdr1 linked with chloroquine resistance[59], 
including the single substitution N86Y (the K1 allele), and four substitutions Y184P, 
N1032D, S1034C and D1246Y (7G8 allele). However, the most convincing demonstration for 
the role of Pfmdr1 has come from recent allelic exchange studies which show that 
replacement of the wild type allele in chloroquine-sensitive strains with resistant alleles 
resulted in decreased drug sensitivity[60]. There is evidence that more than one gene is 
involved in coding for the chloroquine resistance phenotype.  
The P. falciparum Chloroquine Resistance Transporter Gene (Pfcrt) 
Through transfection and allelic exchange experiments between resistant and sensitive 
parasites a chloroquine resistance transporter (Pfcrt) gene was identified, which exhibited 
polymorphisms that matched the chloroquine resistance phenotype without exception. An 
in vivo study in Mali demonstrated close association between Pfcrt and chloroquine 
therapeutic failure[61]. 
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3.1.2 Group II blood schizontocides 
These are monobasic quinoline containing drugs (QCD’s), which include quinine, 
mefloquine and halofantrine. Although their mode of action is thought to be essentially 
similar to that of the chloroquine group in interfering with haemoglobin digestion[62], the 
mechanism of resistance to these antimalarials is not clearly understood.  
Increased drug efflux as seen with chloroquine-resistant P. falciparum, has not been 
demonstrated with the group II blood schizontocides. Moreover, it is believed unlikely that 
group II schizontocides, which are monobasic, can accumulate sufficiently in food vacuoles 
to reach levels required to inhibit haem polymerization[42], yet at least some of these drugs 
are more potent inhibitors of parasite growth than chloroquine. In addition, resistance to 
mefloquine has been associated with Pfmdr1 amplification and cross-resistance to quinine 
and halofantrine, but decreased resistance to chloroquine[63].  
3.2 Resistance to antifolate drugs 
Antifolates include dihydrofolate reductase (DHFR) inhibitors (pyrimethamine, 
trimethoprim, cycloguanil, chlorcycloguanil) and dihydropteroate synthetase (DHPS) 
inhibitors (sulfones and sulfonamides, e.g. sulfadoxine, sulfamethoxazole, dapsone). These 
drugs were also among the first generation of synthetic antimalarials introduced in late 
1940’s [64].  Combinations of pyrimethamine and sulfonamides have been used as second 
line medication to treat chloroquine-resistant P. falciparum infections since the mid-1960's. 
Prophylactic usage was terminated owing to high risk of adverse reactions, except with 
pyrimethamine alone or dapsone/pyrimethamine which remains an alternative 
prophylactic used in a few countries.  
Resistance to pyrimethamine became widespread in large areas soon after introduction of 
the drug, but the potentiating combination with sulfonamides retained effectiveness for 
longer. Resistance to the antifolate combinations initially became a problem in Indochina 
and South America in early 1980's. Pyrimethamine/sulfonamide combinations lost 
therapeutic adequacy in wide areas of South East Asia, western Oceania and South 
America and although they are still relatively effective in Africa, resistance is on the 
increase. Like chloroquine, antifolates have remained useful for relatively longer in Africa 
compared to Asia owing to substantial host immunity reducing the levels of in vivo 
therapeutic failure. 
3.2.1 Mechanism of resistance to antifolate drugs 
Unlike resistance to chloroquine and other quinoline containing drugs, the mechanism of 
antifolate drug resistance is directly related to the mode of drug action. The mechanism is 
also relatively well understood. Resistance to antifolates is known to be due to alterations in 
target enzymes which reduce drug binding affinity[65,66]. These structural alterations are 
caused by point mutations in the dihydrofolate/thymidylate synthetase (DHFR-TS) gene, 
for DHFR inhibitors[67,68] or in the dihydro-6-hydroxymethylpterin pyrophosphokinase-
dihydropteroate synthetase (PPPK-DHPS) gene, for DHPS inhibitors[69,70]. 
Antifolate Resistance Point Mutations in the DHFR-TS gene 
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Point mutations conferring resistance to DHFR inhibitors have been well described for 
pyrimethamine and cycloguanil. A single point mutation (from wild type serine to 
asparagine) at amino acid position 108 in the DHFR domain of the DHFR-TS gene is 
associated with resistance to pyrimethamine, and only marginal decrease in susceptibility to 
cycloguanil. Additional mutations N51I and C59R have been associated with high levels of 
pyrimethamine resistance when they occur in combination with the S108N mutation. A 
mutation S108T, coupled with the mutation A16V, confers resistance to cycloguanil, with 
marginal effect on pyrimethamine sensitivity[71,72]. Cross-resistance to pyrimethamine and 
cycloguanil is conferred by a combination of mutations S108N and I164L, and is even 
heightened when the C59R mutation is also present. 
Polymerase chain reaction (PCR) based assays have been developed, to detect 
pyrimethamine and cycloguanil resistant parasites and their correlation with standard in 
vitro or in vivo drug response profiles have been explored[73,74,75].  
Antifolate Resistance Mutations in the PPPK-DHPS gene 
Mutations conferring resistance to DHPS inhibitors have been also characterized, especially 
for sulfadoxine and sulfamethoxazole, frequently used in synergistic combinations with 
DHFR inhibitors. Point mutations at positions 436, 437, 540, 581 and 613 of the DHPS 
domain of the PPPK-DHPS gene have been implicated[69], with those at positions 436, 437, 
and 581 being reportedly the most common. As with the DHFR inhibitors, a corresponding 
PCR-based assay for detecting PPPK-DHPS mutations conferring resistance to sulfa drugs 
(sulfadoxine and sulfamethoxazole) has been developed.  
4. Point mutations as molecular markers for drug-resistance 
The gold standard approach for monitoring drug resistance is by performing in vivo 
antimalarial drug therapeutic efficacy assessments[35,40]. A complex protocol is 
implemented, where a sentinel group of malaria patients, mostly aged 5 years or less, is 
subjected to supervised drug treatment and followed up for periods usually lasting 28 days. 
Parasitological and clinical response to treatment is monitored during follow-up to ascertain 
whether clearance takes place within the stipulated time consistent with adequate drug 
efficacy. To distinguish persistent or recrudescent parasitaemia from reinfections, pre- and 
post-treatment samples must be subjected to genotyping using polymorphic markers, 
usually P. falciparum MSP1, MSP2 and GLURP genes. This approach is labour-intensive and 
costly, often with losses to follow-up, while some of the patients do not meet eligibility 
criteria at recruitment. Accrual of significant sample sizes on which to base incisive policy 
conclusions is therefore sometimes constrained, especially as malaria cases decrease.  
Needless to say, the molecular detection of point mutations that confer drug resistance has 
proved a highly efficient approach for tracking and containment of drug resistant malaria. 
To date these molecular markers for drug resistance are best characterized for chloroquine 
and antifolate drugs (Table 1). Furthermore, the nature and combination of mutations that 
correlate most closely with clinical failure are characterized by standardizing against the in 
vivo assessment gold standard, making for highly instrumental surveillance tools. In 
antifolate resistance, combinations point mutations (double, triple, quadruple quintuple 
mutants) in the parasite DHFR and DHPS genes confer increasing levels of resistance. 
Research is under way to characterize markers for the other major antimalarials in use.  
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Gene Molecular Marker (Point Mutation) Antimalarial Drug 
PfCRT K76T Chloroquine 
DHFR-TS S108N, S108T, N51I, C59R, A16V, I164L DHFR inhibitors 
pyrimethamine, 
cycloguanil 
PPK-DHPS S436A(F/C ), A437G, L540E, A581G, A613S(T) DHPS inhibitors 
Sulfadoxine 
Table 1. Point mutations widely used to track drug-resistant malaria  
With molecular markers, resistant parasites can now be monitored both in the human and 
vector hosts, enabling containment long before escalation to a public health toll (Figure 1). 
 
Fig. 1. Distribution of P. falciparum antifolate drug resistance alleles in human and mosquito 
hosts. Note major differences reflecting drug and immune selection. Using point mutations 
as molecular markers, drug resistance can be tracked in any phase of the parasite, enabling 
pre-emptive interventions before patient clinical failures set in.   
4.1 Parasite bar-coding 
Recently, SNPs located in numerous sections across the parasite genome have been applied 
as a potent tool to finger-print or bar-code malaria infections. This enables sensitive 
detection of changes in population structure or epidemiology of malaria in a given area in 
relation to interventions or re-invasion. 
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A typical bar-code[76] comprises 20-24 SNPs from across all the chromosomes of the malaria 
parasite, enabling medium-high resolution typing of malarial infections.  
5. Conclusion 
P. falciparum drug resistance persists as a key strategy by which malaria frustrates control 
and elimination efforts. The complex genomic blueprint of P. falciparum has repeatedly 
proven its ability to overcome any widely introduced antimalarial with relative ease. It is 
therefore imperative to develop and implement not only new antimalarial drugs, but also 
effective strategies for the surveillance and containment of drug resistance. Combination 
therapy is now stipulated as standard treatment for malaria by WHO, where constituent 
drugs protect each other from resistance development and the chances of resistance to both 
are less likely to occur. Artemisinin-based combination therapy (ACT) is preferred, 
containing artemisinin or its derivative as one of the partner drugs, since it is fast-acting and 
shows signs of relatively slow resistance development.  
Simple point mutations can confer resistance to most antimalarial drugs. In the diverse and 
dynamic epidemiology of malaria, point mutations are increasingly adopted as efficient 
molecular markers  for surveillance of drug resistant malaria in endemic countries. These 
molecular markers are readily standardizable and independent of host immune status, drug 
history or other confounding factors incorporated in the strict eligibility criteria for gold 
standard in vivo drug efficacy assessments. They are also less laborious and require much 
less time to perform once standardized against the gold standard in vivo assessments. Well 
characterized molecular markers for resistance to chloroquine and antifolate drugs have 
become standard surveillance tools, with global data being fed into world resistance 
monitoring programmes such as the World-wide Antimalarial Resistance Network 
(WWARN).  
In recent times point mutations are also being utilized to identify malaria strains and detect 
changes in population structure during interventions or resurgences by bar-coding.   
Furthermore, molecular markers for resistance to other major antimalarial drugs are being 
actively sought, placing the simple point mutation in good stead to be the future of 
surveillance in malaria and other diseases. 
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